Brief: Rani Therapeutics Announces Positive Topline Results From Phase 1 Study Of An Oral Anti-Interleukin 12/23 Antibody
05/02/2024 13:14
Feb 5 (Reuters) - Rani Therapeutics Holdings Inc
RANI.O :
* RANI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM
PHASE
1 STUDY OF AN ORAL ANTI-INTERLEUKIN 12/23 ANTIBODY (RT-111)
* RANI THERAPEUTICS HOLDINGS INC: RT-111 WAS WELL-TOLERATED,
WITH
NO SERIOUS ADVERSE EVENTS
* RANI THERAPEUTICS HOLDINGS INC: RT-111 ACHIEVED HIGH
BIOAVAILABILITY IN HUMANS
Source text for Eikon: ID:nGNX8zTQKD
Further company coverage: RANI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rani Therapeutics Holdings
See all newsRani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Brief: Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: Rani Therapeutics Announces R&D Collaboration With PegBio
Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition